Cosmos Health (COSM) EBITDA Margin (2014 - 2026)
Cosmos Health's (COSM) quarterly EBITDA Margin came in at 14.82% in Q2 2026, up 246.0% on a YoY basis from 4.28% in Q2 2025, and down 28.24% quarter-over-quarter from 11.56% in Q1 2026.
Powered by 
Analysis
Cosmos Health (COSM) EBITDA Margin (2014 - 2026) Analysis & Trends
Cosmos Health (COSM) has reported EBITDA Margin for 12 consecutive years, with 14.82% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, EBITDA Margin rose 246.0% year-over-year to 14.82%; the trailing twelve-month figure through Jun 2026 stood at 24.56% (up 143.0% YoY), and the FY2025 full-year result was 24.92%, up 293.0% from the prior year.
- EBITDA Margin retreated to 14.82% in Q2 2026 per COSM's latest filing, from 11.56% in the prior quarter.
- Across five years, EBITDA Margin topped out at 2.5% in Q1 2022 and bottomed at 85.04% in Q4 2023.
- Historically, EBITDA Margin has averaged 24.3% across 5 years, with a median of 17.3% in 2024.
- The sharpest annual moves came in 2022 and 2024: EBITDA Margin slumped 5950 bps in 2022, then soared 2257 bps in 2024.
- Over 5 years, EBITDA Margin stood at 62.04% in 2022, then tumbled by 37 bps to 85.04% in 2023, then climbed by 27 bps to 62.47% in 2024, then increased by 7 bps to 57.89% in 2025, then jumped by 74 bps to 14.82% in 2026.
- According to Business Quant data, EBITDA Margin over the past three periods registered 14.82%, 11.56%, and 57.89% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.33 Bn | 38.68 Bn | 2.15 Bn | -5.58% |
| 2 | Viatris | 19.05 Bn | 18.16 Bn | 1.46 Bn | 0.17% |
| 3 | Dr Reddys Laboratories | 9.76 Bn | 9.58 Bn | 396.53 Mn | 4.69% |
| 4 | Amneal Pharmaceuticals | 5.38 Bn | 5.25 Bn | 334.51 Mn | 16.30% |
| 5 | Bausch Health Companies | 2.27 Bn | 436.38 Mn | 2.10 Bn | 25.95% |
| 6 | Alvotech | 1.51 Bn | 1.37 Bn | 2.56 Mn | -134.08% |
| 7 | Ani Pharmaceuticals | 1.51 Bn | 1.15 Bn | 165.89 Mn | 15.21% |
| 8 | Amphastar Pharmaceuticals | 1.03 Bn | 737.26 Mn | 93.47 Mn | 21.60% |
| 9 | Fennec Pharmaceuticals | 393.12 Mn | 351.87 Mn | 17.15 Mn | 9.72% |
| 10 | Cosmos Health | 15.08 Mn | 12.63 Mn | 1.51 Mn | -14.82% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.82% |
| Mar 31, 2026 | -11.56% |
| Dec 31, 2025 | -57.89% |
| Sep 30, 2025 | -10.63% |
| Jun 30, 2025 | -17.28% |
| Mar 31, 2025 | -5.36% |
| Dec 31, 2024 | -62.47% |
| Sep 30, 2024 | -17.32% |
| Jun 30, 2024 | -18.16% |
| Mar 31, 2024 | -11.82% |
| Dec 31, 2023 | -85.04% |
| Sep 30, 2023 | -22.55% |
| Jun 30, 2023 | -19.83% |
| Mar 31, 2023 | -20.94% |
| Dec 31, 2022 | -62.04% |
| Sep 30, 2022 | -2.17% |
| Jun 30, 2022 | 0.05% |
| Mar 31, 2022 | 2.50% |
| Dec 31, 2021 | -2.54% |
| Sep 30, 2021 | -6.22% |